Zydus Therapeutics Inc. clinical trials

A subsidiary of Zydus Lifesciences Limited

The registry lists 19 studies whose lead sponsor is Zydus Therapeutics Inc.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 21, 2026.

Studies

Recruiting first, then most recently updated. Showing 19 of 19. All Zydus Lifesciences Limited studies →

• Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyRecruitingNCT07424677Phase 3

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Hepatic Impairment With Cirrhosis Due to Cholestatic Liver DiseaseRecruitingNCT05045482Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver DiseaseRecruitingNCT06825559Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral SclerosisRecruitingNCT07023835Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesRecruitingNCT07216235Phase 3

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisCompletedNCT05011305Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisCompletedNCT05133336Phase 2/3

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary CholangitisActive, not recruitingNCT06427395Phase 3

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)TerminatedNCT03617263Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USTerminatedNCT05211284Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT03639623Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisCompletedNCT03061721Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium in the Treatment of Non-Alcoholic SteatohepatitisCompletedNCT03863574Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic FunctionCompletedNCT04469920Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal FunctionCompletedNCT04446507Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary CholangitisCompletedNCT03112681Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dLSuspendedNCT03097107Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy VolunteersCompletedNCT04045769Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male SubjectsCompletedNCT04112446Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.